Cas:91805-17-3 naphthalen-2-yl prop-2-ynoate manufacturer & supplier

Chemical Name:naphthalen-2-yl prop-2-ynoate

CAS.NO:91805-17-3

Synonyms:2-Naphthyl propiolate;Propiolsaeure-<2>-naphtylester

Molecular Formula:C₁₃H₈O₂

Molecular Weight:196.20100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:26.30000

Exact Mass:196.05200

LogP:2.37840

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 3077 9 / PGIII

Packing Group:

Contact us for information like 2-Naphthyl propiolate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,-naphtylester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Propiolsaeure-&lt Use and application,Propiolsaeure-&lt technical grade,usp/ep/jp grade.

Related News: These include: high-barrier generic drug substances and commonly used generic drug substances. naphthalen-2-yl prop-2-ynoate manufacturer The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances. naphthalen-2-yl prop-2-ynoate supplier We have leading expertise in strategy and operational implementation of pre-approval access programs making pharmaceutical products under clinical development available for patients and Inceptua��s clinical trial services business offers high quality clinical comparator sourcing and manufacturing services with an agile global supply chain to ensure that products are delivered exactly when needed. naphthalen-2-yl prop-2-ynoate vendor In a memo to Branchburg employees on May 20, Nellie Clark, head of the plant, summed up the outside lawyers’ findings: “In the end and very importantly, allegations that Lilly made false statements to the FDA were not substantiated.” naphthalen-2-yl prop-2-ynoate factory In a memo to Branchburg employees on May 20, Nellie Clark, head of the plant, summed up the outside lawyers’ findings: “In the end and very importantly, allegations that Lilly made false statements to the FDA were not substantiated.”